Median Technologies Clears FDA Hurdle for U.S. Lung Cancer Screening AI
Event summary
- Median Technologies received FDA 510(k) clearance for eyonis® LCS, enabling U.S. commercial deployment.
- Established Median Eyonis Inc. to lead U.S. operations, appointing Oran Muduroglu as President.
- Partnered with Tempus to accelerate eyonis® LCS adoption in the U.S.
- Hosting investor webcasts on February 26, 2026, to detail U.S. go-to-market strategy.
The big picture
Median Technologies' FDA clearance for eyonis® LCS positions it to tap into the $1.5B U.S. lung cancer screening market, where AI-driven diagnostics are gaining traction. The move aligns with broader trends in digital health, where regulatory approvals are becoming key differentiators for AI SaMD providers. Success will hinge on Median's ability to navigate U.S. healthcare complexities and compete with established imaging players.
What we're watching
- Regulatory Momentum
- Whether FDA clearance will accelerate eyonis® LCS adoption beyond initial U.S. rollout.
- Execution Risk
- The pace at which Median can scale U.S. operations and meet commercialization targets.
- Partnership Impact
- How Tempus collaboration will influence eyonis® LCS market penetration and revenue growth.
Related topics